Fragment-Based Drug Discovery

Small Molecule Medicinal Chemistry: Strategies and Technologies

Volumn , Issue , 2015, Pages 221-249

  Renaud, Jean Paul ^a   Neumann, Thomas ^a   Van Hijfte, Luc ^a  

^a Building A: Chemistry   (France)

Author keywords

Biophysical screening technologies; FBDD case studies; Fragment evolution strategies; Fragment libraries; Fragment based drug discovery

Indexed keywords

DRUG PRODUCTS; LIBRARIES; MASS SPECTROMETRY; NUCLEAR MAGNETIC RESONANCE; SURFACE PLASMON RESONANCE;

BIOPHYSICAL TECHNIQUES; CASE-STUDIES; DIFFERENTIAL SCANNING FLUORIMETRY; DRUG DISCOVERY; DRUG DISCOVERY PROCESS; EVOLUTION STRATEGIES; NUCLEAR MAGNETIC RESONANCE (NMR); SCREENING TECHNOLOGY;

X RAY CRYSTALLOGRAPHY;

EID: 84960263055     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118771723.ch8     Document Type: Chapter

References (100)

1. Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, Schacht AL (2010). How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat. Rev. Drug Discov. 9: 203-214.
2. Pammolli F, Magazzini L, Riccaboni M (2011). The productivity crisis in pharmaceutical R&D. Nat. Rev. Drug Discov. 10: 428-438.
3. Hajduk PJ, Greer J (2007). A decade of fragment-based drug design: strategic advances and lessons learned. Nat. Rev. Drug Discov. 6: 211-219.
4. Jahnke W, Erlanson DA (Eds) (2006). Fragment-based Approaches in Drug Discovery (Weinheim: Wiley-VCH).
5. Erlanson DA, McDowell RS, O'Brien T (2004). Fragment-based drug discovery. J. Med. Chem. 47: 3463-3482.
6. Warr W (2009). Fragment-based drug discovery. J. Comput. Aided Mol. Des. 23: 453-458.
7. Congreve M, Chessari G, Tisi D, Woodhead AJ (2008). Recent developments in fragmentbased drug discovery. J. Med. Chem. 51: 3661-3680.
8. Chessari G, Woodhead AJ (2009). From fragment to clinical candidate-a historical perspective. Drug Discov. Today 14: 668-675.
9. Coyne AG, Scott DE, Abell C (2010). Drugging challenging targets using fragment based approaches. Curr. Opin. Chem. Biol. 14: 299-307.
10. Whittaker M, Law RJ, Ichihara O, Hesterkamp T, Hallett D (2010). Fragments: past, present and future. Drug Discov. Today 7: 163-171.
11. Murray W, Verdonk M, Rees DC (2012). Experiences in fragment-based drug discovery. Trends Pharmacol. Sci. 33(5): 224-232.
12. Hubbard RE, Murray JB (2011). Experiences in fragment-based lead discovery. Methods Enzymol. 493: 509.
13. Erlanson DA, Zartler E. Available at: http://practicalfragments.blogspot.fr/2015/01/fragmentsin-clinic-2015-edition.html (accessed July 28, 2015).
14. Michne WF (1996). Hit-to-lead chemistry: a key element in new lead generation. Pharmaceut. News 3: 19-21.
15. Shuker SB, Hajduk PJ, Meadows RP, Fesik SW (1996). Discovering high-affinity ligands for proteins: SAR by NMR. Science 274: 1531-1534.
16. Baker M (2013). Fragment-based lead discovery grows up. Nat. Rev. Drug Discov. 12: 5-7.
17. Fink T, Reymond JL (2007). Virtual exploration of the chemical universe up to 11 atoms of C, N, O, F: assembly of 26.4 million structures (110.9 million stereoisomers) and analysis for new ring systems, stereochemistry, physicochemical properties, compound classes, and drug discovery. J. Chem. Inf. Model. 47: 342-353.
18. Boyd S, Turnbull A, Walse B (2012). Fragment library design considerations. WIREs Comput. Mol. Sci. 2: 868-885.
19. Schulz MN, Landström J, Bright K, Hubbard RE (2011). Design of a fragment library that maximally represents available chemical space. J. Comput. Aided Mol. Des. 25: 611-620.
20. Over B, Wetzel S, Grütter C, Nakai Y, Renner S, Rauh D, Waldmann H (2013). Natural-productderived fragments for fragment-based ligand discovery. Nat. Chem. 5: 21-28.
21. Jencks W (1981). On the attribution and additivity of binding energies. Proc. Natl. Acad. Sci. U. S. A. 78: 4046-4050.
22. Erlanson D (2014). Poll results: affiliation, fragment-finding methods, and library size. Available at: http://practicalfragments.blogspot.fr/2014/01/poll-results-affiliation-fragment. html (accessed May 13, 2015).
23. Hennig M, Ruf A, Huber W (2011). Combining biophysical screening and X-ray crystallography for fragment-based drug discovery. Top. Curr. Chem. 317: 115-143.
24. Schasfoort RBM, Tudos AJ (Eds) (2008). Handbook of Surface Plasmon Resonance (Cambridge: RSH Publishing).
25. Rich RL, Myszka DG (2008). Survey of the year 2007 commercial optical biosensor literature. J. Mol. Recognit. 21(6): 355-400.
26. Rothenhausler B, Knoll W (1988). Surface-plasmon microscopy. Nature 332: 615-617.
27. Zizlsperger M, Knoll W (1998). Multispot parallel on-line monitoring of interfacial binding reactions by surface plasmon microscopy. Progr. Colloid Polym. Sci. 109: 244-253.
28. Campell CT, Kim G (2007). SPR microscopy and its applications to high-throughput analyses of biomolecular binding events and their kinetics. Biomaterials 28: 2380-2392.
29. Neumann T, Junker HD, Schmidt K, Sekul R (2007). SPR-based fragment screening: advantages and applications. Curr. Top. Med. Chem. 7(16): 1630-1642.
30. Dickopf S, Frank M, Junker HD, Maier S, Metz G, Ottleben H, Rau H, Schellhaas N, Schmidt K, Sekul R, Vanier C, Vetter D, Czech J, Lorenz M, Matter H, Schudok M, Schreuder H, Will DW, Nestler HP (2004). Custom chemical microarray production and affinity fingerprinting for the S1 pocket of factor VIIa. Anal. Biochem. 335(1): 50-57.
31. Heim-Riether A, Taylor SJ, Liang S, Gao DA, Xiong Z, Michael August E, Collins BK, Farmer BT, Haverty K, Hill-Drzewi M, Junker HD, Mariana Margarit S, Moss N, Neumann T, Proudfoot JR, Keenan LS, Sekul R, Zhang Q, Li J, Farrow NA (2009). Improving potency and selectivity of a new class of non-Zn-chelating MMP-13 inhibitors. Bioorg. Med. Chem. Lett. 19(18): 5321-5324.
32. Neumann T, Junker HD, Keil O, Burkert K, Ottleben H, Gamer J, Sekul R, Deppe H, Feurer A, Tomandl D, Metz G (2005). Discovery of thrombin inhibitor fragments from chemical microarray screening. Lett. Drug Des. Discovery 2: 563-566.
33. Neumann T, Sekul R (2011). SPR screening of chemical microarrays for fragment based discovery. In Label-Free Technologies for Drug Discovery, Ed. LM Mayr, MA Cooper (Chichester: John Wiley & Sons, Ltd), pp 42-45.
34. Arnold M, Bittermann H, Kalbfuss-Zimmermann B, Neumann T, Schmidt K, Sekul R, Hilbrig F, Ludolph H, Freitag R (2011). Antibody purification by affinity chromatography based on small molecule affinity ligands identified by SPR-based screening of chemical microarrays. J. Chromatogr. A 1218(29): 4649-4659 (in eng).
35. Stockman BJ, Dalvit C (2002). NMR screening techniques in drug discovery and drug design. Prog. Nucl. Magn. Reson. Spectrosc. 41: 187-231.
36. Lepre CA, Moore JM, Peng JW (2004). Practical aspects of NMR-based fragment screening. Chem. Rev. 104: 3641-3676.
37. Lepre CA (2011). Theory and applications of NMR-based screening in pharmaceutical research. Methods Enzymol. 493: 219-239.
38. Pellecchia M, Bertini I, Cowburn D, Dalvit D, Giralt E, Jahnke W, James TL, Homans SW, Kessler H, Luchinat C, Meyer B, Oschkinat H, Peng J, Schwalbe H, Siegal S (2008). Perspectives on NMR in drug discovery: a technique comes of age. Nat. Rev. Drug Discov. 7: 738-745.
39. Hajduk PJ, Olejniczak ET, Fesik SW (1997). One-dimensional relaxation-and diffusionedited NMR methods for screening compounds that bind to macromolecules. J. Am. Chem. Soc. 119: 12257-12261.
40. Mayer M, Meyer B (1999). Characterization of ligand binding by saturation transfer difference NMR spectroscopy. Angew. Chem. Int. Ed. 38: 1784-1788.
41. Dalvit C, Fogliatto G, Stewart A, Veronesi M, Stockman B (2001). WaterLOGSY as a method for primary NMR screening: practical aspects and range of applicability. J. Biomol. NMR 21: 349-359.
42. Meyer B, Peters T (2003). NMR spectroscopy techniques for screening and identifying ligand binding to protein receptors. Angew. Chem. Int. Ed. 42: 864-890.
43. Dalvit C, Flocco M, Knapp S, Mostardini M, Perego R, Stockman BJ, Veronesi M, Varasi M (2002). High-throughput NMR-based screening with competition binding experiments. J. Am. Chem. Soc. 124: 7702-7709.
44. Jahnke W, Floersheim P, Ostermeier C, Zhang X, Hemmig R, Hurth K, Uzunov DP (2002). NMR reporter screening for the detection of high-affinity ligands. Angew. Chem. Int. Ed. 41: 3420-3423.
45. Dalvit C (2007). Ligand-and substrate-based 19F NMR screening: principles and applications to drug discovery. Prog. Nucl. Magn. Reson. Spectrosc. 51: 243-271.
46. Dalvit C, Fagerness PE, Hadden DT, Sarver RW, Stockman BJ (2003). Fluorine-NMR experiments for high-throughput screening: theoretical aspects, practical considerations, and range of applicability. J. Am. Chem. Soc. 125: 7696-7703.
47. Mayer M, Meyer B (2001). Group epitope mapping by saturation transfer difference NMR to identify segments of a ligand in direct contact with a protein receptor. J. Am. Chem. Soc. 123: 6108-6117.
48. Sanchez-Pedregal VM, Reese M, Meiler J, Blommers MJ, Griesinger C, Carlomagno T (2005). The INPHARMA method: protein-mediated interligand NOEs for pharmacophore mapping. Angew. Chem. Int. Ed. 44: 4172-4175.
49. Ludwig C, Michiels PJ, Wu X, Kavanagh KL, Pilka E, Jansson A, Oppermann U, Günther UL (2008). SALMON: solvent accessibility, ligand binding, and mapping of ligand orientation by NMR spectroscopy. J. Med. Chem. 51: 1-3.
50. Wagstaff JL, Taylor SL, Howard MJ (2013). Recent developments and applications of saturation transfer difference nuclear magnetic resonance (STD NMR) spectroscopy. Mol. Biosyst. 9: 571-577.
51. Śledź P, Abell C, Ciulli A (2012). Ligand-observed NMR in fragment-based approaches. In NMR of Biomolecules: Towards Mechanistic Systems Biology, Ed. I Bertini, KS McGreevy, G Parigi (Weinheim: Wiley-VCH), pp 264-280.
52. Dalvit C (2009). NMR methods in fragment screening: theory and a comparison with other biophysical techniques. Drug Discov. Today 14: 1051-1057.
53. Maurer T, Garrenton LS, Oh A, Pitts K, Anderson DJ, Skelton NJ, Fauber BP, Pan B, Malek S, Stokoe D, Ludlam MJ, Bowman KK, Wu J, Giannetti AM, Starovasnik MA, Mellman I, Jackson PK, Rudolph J, Wang W, Fang G (2012). Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity. Proc. Natl. Acad. Sci. U. S. A. 109: 5299-5304.
54. Verlinde CL, Fan E, Shibata S, Zhang Z, Sun Z, Deng W, Ross J, Kim J, Xiao L, Arakaki TL, Bosch J, Caruthers JM, Larson ET, Letrong I, Napuli A, Kelly A, Mueller N, Zucker F, Van Voorhis WC, Buckner FS, Merritt EA, Hol WG (2009). Fragment-based cocktail crystallography by the medical structural genomics of pathogenic protozoa consortium. Curr. Top. Med. Chem. 9: 1678-1687.
55. Nienaber VL, Richardson PL, Klighofer V, Bouska JJ, Giranda VL, Greer J (2000). Discovering novel ligands for macromolecules using X-ray crystallographic screening. Nat. Biotechnol. 18: 1105-1108.
56. Blundell TL, Jhoti H, Abell C (2002). High-throughput crystallography for lead discovery in drug design. Nat. Rev. Drug Discov. 1: 45-54.
57. Lesuisse D, Lange G, Deprez P, Bénard D, Schoot B, Delettre G, Marquette JP, Broto P, Jean-Baptiste V, Bichet P, Sarubbi E, Mandine E (2002). SAR and X-ray. A new approach combining fragment-based screening and rational drug design: application to the discovery of nanomolar inhibitors of Src SH2. J. Med. Chem. 45: 2379-2387.
58. Davies TG, Tickle IJ (2012). Fragment screening using X-ray crystallography. Top. Curr. Chem. 317: 33-59.
59. Jhoti H, Cleasby A, Verdonk M, Williams G (2007). Fragment-based screening using X-ray crystallography and NMR spectroscopy. Curr. Opin. Chem. Biol. 11: 485-493.
60. Wasserman SR, Koss JW, Sojitra ST, Morisco LL, Burley SK (2012). Rapid-access, highthroughput synchrotron crystallography for drug discovery. Trends Pharmacol. Sci. 33: 261-267.
61. Ganem B, Li YT, Henion JD (1991). Detection of noncovalent receptor-ligand complexes by mass spectrometry. J. Am. Chem. Soc. 113: 6294-6296.
62. Katta V, Chait BT (1991). Observation of the heme-globin complex in native myoglobin by electrospray-ionization mass spectrometry. J. Am. Chem. Soc. 113: 8534-8535.
63. Sanglier S, Atmanene C, Chevreux G, Van Dorsselaer A (2008). Nondenaturing mass spectrometry to study noncovalent protein/protein and protein/ligand complexes: technical aspects and application to the determination of binding stoichiometries. In Functional Proteomics: Methods and Protocols, Methods in Molecular Biology, vol. 484, Ed. C Schaeffer-Reiss, JD Thompson, M Ueffing (Totowa, NJ: Humana Press), pp 217-243.
64. Vivat Hannah V, Atmanene C, Zeyer D, Van Dorsselaer A, Sanglier-Cianférani S (2010). Native MS: an "ESI" way to support structure-and fragment-based drug discovery. Future Med. Chem. 2: 35-50.
65. Erlanson DA, Braisted AC, Raphael DR, Randal M, Stroud RM, Gordon EM, Wells JA (2000). Site-directed ligand discovery. Proc. Natl. Acad. Sci. U. S. A. 97: 9367-9372.
66. Erlanson DA, Wells JA, Braisted AC (2004). Tethering: fragment-based drug discovery. Annu. Rev. Biophys. Biomol. Struct. 33: 199-223.
67. Duong-Thi MD, Meiby E, Bergström M, Fex T, Isaksson R, Ohlson S (2011). Weak affinity chromatography as a new approach for fragment screening in drug discovery. Anal. Biochem. 414: 138-146.
68. Lo MC, Aulabaugh A, Jin G, Cowling R, Bard J, Malamas M, Ellestad G (2004). Evaluation of fluorescence-based thermal shift assays for hit identification in drug discovery. Anal. Biochem. 332: 153-159.
69. Niesen FH, Berglund H, Vedadi M (2007). The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability. Nat. Protoc. 2: 2212-2221.
70. Dai R, Wilson DJ, Geders TW, Aldrich CC, Finzel BC (2014). Inhibition of Mycobacterium tuberculosis transaminase BioA by aryl hydrazines and hydrazides. Chembiochem 15: 575-586.
71. Cimmperman P, Baranauskiene L, Jachimoviciūte S, Jachno J, Torresan J, Michailoviene V, Matuliene J, Sereikaite J, Bumelis V, Matulis D (2008). A quantitative model of thermal stabilization and destabilization of proteins by ligands. Biophys. J. 95: 3222-3231.
72. Mashalidis EH, Śledź P, Lang S, Abell C (2013). A three-stage biophysical screening cascade for fragment-based drug discovery. Nat. Protoc. 8: 2309-2324.
73. Davis BJ, Erlanson DA (2013). Learning from our mistakes: The "unknown knowns" in fragment screening. Bioorg. Med. Chem. Lett. 23: 2844-2852.
74. Alexandrov AI, Mileni M, Chien EY, Hanson MA, Stevens RC (2008). Microscale fluorescent thermal stability assay for membrane proteins. Structure 16: 351-359.
75. Navratilova I, Besnard J, Hopkins AL (2011). Screening for GPCR ligands using surface plasmon resonance. ACS Med. Chem. Lett. 2: 549-554.
76. Seeger C, Christopeit T, Fuchs K, Grote K, Sieghart W, Danielson UH (2012). Histaminergic pharmacology of homo-oligomeric β3 γ-aminobutyric acid type A receptors characterized by surface plasmon resonance biosensor technology. Biochem. Pharmacol. 84: 341-351.
77. Aristotelous T, Ahn S, Shukla AK, Gawron S, Sassano MF, Kahsai AW, Wingler LM, Zhu X, Tripathi-Shukla P, Huang XP, Riley J, Besnard J, Read KD, Roth BL, Gilbert IH, Hopkins AL, Lefkowitz RJ, Navratilova I (2013). Discovery of β2 adrenergic receptor ligands using biosensor fragment screening of tagged wild-type receptor. ACS Med. Chem. Lett. 4: 1005-1010.
78. Yanamala N, Dutta A, Beck B, van Vliet B, Hay K, Yazbak A, Ishima R, Doemling A, Klein-Seetharaman J (2010). NMR-based screening of membrane protein ligands. Chem. Biol. Drug Des. 75: 237-256.
79. Congreve M, Rich RL, Myszka DG, Figaroa F, Siegal G, Marshall FH (2011). Fragment screening of stabilized G-protein-coupled receptors using biophysical methods. Methods Enzymol. 493: 115-136.
80. Chen D, Errey JC, Heitman LH, Marshall FH, Ijzerman AP, Siegal G (2012). Fragment screening of GPCRs using biophysical methods: identification of ligands of the adenosine A(2A) receptor with novel biological activity. ACS Chem. Biol. 7: 2064-2073.
81. Christopher JA, Brown J, Doré AS, Errey JC, Koglin M, Marshall FH, Myszka DG, Rich RL, Tate CG, Tehan B, Warne T, Congreve M (2013). Biophysical fragment screening of the β1-adrenergic receptor: identification of high affinity arylpiperazine leads using structure-based drug design. J. Med. Chem. 56: 3446-3455.
82. Wells JA, McClendon CL (2007). Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 450: 1001-1009.
83. Mullard A (2012). Protein-protein interaction inhibitors get into the groove. Nat. Rev. Drug Discov. 11: 173-175.
84. Thompson AD, Dugan A, Gestwicki JE, Mapp AK (2012). Fine-tuning multiprotein complexes using small molecules. ACS Chem. Biol. 7: 1311-1320.
85. Valkov E, Sharpe T, Marsh M, Greive S, Hyvönen M (2012). Targeting protein-protein interactions and fragment-based drug discovery. Top. Curr. Chem. 317: 145-179.
86. Moreira IS, Fernandes PA, Ramos MJ (2007). Hot spots-a review of the protein-protein interface determinant amino-acid residues. Proteins 68: 803-812.
87. Winter A, Higueruelo AP, Marsh M, Sigurdardottir A, Pitt WR, Blundell TL (2012). Biophysical and computational fragment-based approaches to targeting protein-protein interactions: applications in structure-guided drug discovery. Q. Rev. Biophys. 45: 383-426.
88. Barile E, Pellecchia M (2014). NMR-based approaches for the identification and optimization of inhibitors of protein-protein interactions. Chem. Rev. 114(9): 4749-4763.
89. Scott DE, Ehebauer MT, Pukala T, Marsh M, Blundell TL, Venkitaraman AR, Abell C, Hyvönen M (2013). Using a fragment-based approach to target protein-protein interactions. Chembiochem 14: 332-342.
90. Dias DM, Van Molle I, Baud MGJ, Galdeano C, Geraldes CFGC, Ciulli A (2014). Is NMR fragment screening fine-tuned to assess druggability of protein-protein interactions? ACS Med. Chem. Lett. 5: 23.
91. Schultes S, de Graaf C, Haaksma E, de Esch I, Leurs R, Kramer O (2010). Ligand efficiency as a guide in fragment hit selection and optimization. Drug Discov. Today 7: 157-162.
92. Howard S, Berdini V, Boulstridge JA, Carr MG, Cross DM, Curry J, Devine LA, Early TR, Fazal L, Gill AL, Heathcote M, Maman S, Matthews JE, McMenamin RL, Navarro EF, O'Brien MA, O'Reilly M, Rees DC, Reule M, Tisi D, Williams G, Vinković M, Wyatt P (2009). Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity. J. Med. Chem. 52: 379-388.
93. Filippakopoulos P, Knapp S (2014). Targeting bromodomains: epigenetic readers of lysine acetylation. Nat. Rev. Drug Discov. 13: 337-356.
94. Bamborough P, Diallo H, Goodacre JD, Gordon L, Lewis A, Seal JT, Wilson DM, Woodrow MD, Chung C (2012). Fragment-based discovery of bromodomain inhibitors part 2: optimization of phenylisoxazole sulfonamides. J. Med. Chem. 55: 587-596.
95. Tanaka D, Tsuda Y, Shiyama T, Nishimura T, Chiyo N, Tominaga Y, Sawada N, Mimoto T, Kusunose N (2011). A practical use of ligand efficiency indices out of the fragment-based approach: ligand efficiency-guided lead identification of soluble epoxide hydrolase inhibitors. J. Med. Chem. 54: 851-857.
96. Barelier S, Pons J, Marcillat O, Lancelin JM, Krimm I (2010). Fragment-based deconstruction of Bcl-xL inhibitors. J. Med. Chem. 53: 2577-2588.
97. Giannetti AM, Zheng X, Skelton NJ, Wang W, Bravo BJ, Bair KW, Baumeister T, Cheng E, Crocker L, Feng Y, Gunzner-Toste J, Ho Y, Hua R, Liederer BM, Liu Y, Ma X, O'Brien T, Oeh J, Sampath D, Shen Y, Wang C, Wang L, Wu H, Xiao Y, Yuen P, Zak M, Zhao G, Zhao Q, Dragovich PS (2014). Fragment-based identification of amides derived from trans-2-(pyridin-3-yl)cyclopropanecarboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT). J. Med. Chem. 57(3): 770-792.
98. Hirose T, Maita N, Gouda H, Koseki J, Yamamoto T, Sugawara A, Nakano H, Hirono S, Shiomi K, Watanabe T, Taniguchi H, Sharpless KB, Omura S, Sunazuka T (2013). Observation of the controlled assembly of preclick components in the in situ click chemistry generation of a chitinase inhibitor. Proc. Natl. Acad. Sci. U. S. A. 110(40): 15892-15897.
99. Lehn JM, Eliseev AV (2001). Dynamic combinatorial chemistry. Science 291(5512): 2331-2332.
100. Zartler E (2014). Fragonomics: the-omics with real impact. ACS Med. Chem. Lett. 5(9): 952-953.